REVIEW article
Front. Psychiatry
Sec. Psychopharmacology
Volume 16 - 2025 | doi: 10.3389/fpsyt.2025.1659290
Optimizing Long-Acting Injectable Antipsychotic Safety and Care Continuity Through Documentation Best Practices
Provisionally accepted- 1College of Pharmacy, University of Tennessee Health Science Center, Memphis, United States
- 2Department of Psychiatry and Behavioral Neurobiology, The University of Alabama at Birmingham Heersink School of Medicine, Birmingham, United States
- 3Department of Pharmacy, University of Alabama at Birmingham Medical Center, Birmingham, United States
Select one of your emails
You have multiple emails registered with Frontiers:
Notify me on publication
Please enter your email address:
If you already have an account, please login
You don't have a Frontiers account ? You can register here
Background: Long-acting injectable antipsychotics (LAI-APs) are vital for managing psychiatric conditions, particularly in patients with adherence challenges. However, errors in medication reconciliation, prescribing, preparation, and administration, often stemming from documentation lapses and communication breakdowns, may result in an increased risk of relapse or readmission. Despite their widespread use, standardized documentation practices remain underdeveloped.Objective: To identify documentation insufficiencies related to LAI-AP use across healthcare settings and propose best practice recommendations to improve safety and care continuity.A comprehensive review of literature using PubMed, Google Scholar, current clinical guidelines, and gray literature was conducted to identify safety concerns and documentation gaps related to LAI-APs. Search terms included "LAI antipsychotic medication errors," "documentation," "safety," "mental health," and "medication reconciliation." Further articles were identified through a scan of the references cited within the initial sources. From this analysis, a series of best practice recommendations were developed targeting key aspects of LAI-AP use, with a focus on practical implementation strategies.Results: Limited literature is available on errors related to LAI-AP with minimal detail on documentation strategies to address these. By reviewing reports, extrapolating recommendations from their oral antipsychotic counterparts, and analyzing potential risk factors unique to the behavioral health setting, key documentation gaps were identified across the LAI-AP use process.These include deficiencies in medication reconciliation-especially related to last doses and oral overlap-along with inconsistencies in prescribing practices, patient education, preparation, administration, and transitions of care. Inadequate documentation contributes to missed or duplicate doses, incorrect administration techniques, and poor coordination between settings. Our findings indicate the need for standardized order sets, readily accessible documentation of initiation or discontinuation reasoning, integration of therapeutic drug monitoring and symptom tracking tools, structured patient education, and formalized transitions of care procedures.Conclusion: Enhancing documentation throughout the LAI-AP care continuum is crucial to reduce medication errors and improve patient outcomes. The proposed framework offers practical steps for clinicians and health systems to standardize documentation, improve communication during care transitions, and promote safer LAI-AP use. Innovations such as national electronic health records, EHR-integrated LAI-AP registries, and smartphone apps could facilitate cross-setting communication, patient engagement, and error reduction. Addressing systemic barriers will require policy-level reform.
Keywords: Documentation, Long-acting injectable antipsychotics, Medication Reconciliation, antipsychotic depots, EHR interoperability, best practices, Transitions of care, psychiatric medication safety
Received: 03 Jul 2025; Accepted: 28 Jul 2025.
Copyright: © 2025 Throneberry, Burk and Pruett. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
* Correspondence: Amie Rae Throneberry, College of Pharmacy, University of Tennessee Health Science Center, Memphis, United States
Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.